Pharmacy Medical News about Breast Neoplasms Drug Resistance, Neoplasm

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
Clinical Therapeutics, 10/15/09

Moreno–Aspitia A et al. – Previous research has reported the efficacy of capecitabine, gemcitabine, nanoparticle albumin–bound paclitaxel, and ixabepilone in the treatment of metastatic BC in patients who have already been treated with anthracyclines and/or taxanes. Such patients previously had few treatment options. Ongoing investigations into novel combination regimens with these agents, including combinations with targeted agents, may further build on this progress. Further research is needed to understand the economic implications of these regimens, including the broader societal effects and the value to patients.

<< Previous
Clinical and Economic Comparison of Frovatriptan Versus other...

Next >>
Pharmacokinetics and Antihypertensive Effects of Candesartan...